1. Home
  2. RPC vs CMPX Comparison

RPC vs CMPX Comparison

Compare RPC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ridgepost Capital Inc. Class A Common Stock

RPC

Ridgepost Capital Inc. Class A Common Stock

N/A

Current Price

$6.90

Market Cap

932.7M

Sector

Finance

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.19

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPC
CMPX
Founded
1992
2014
Country
United States
United States
Employees
267
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
932.7M
927.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RPC
CMPX
Price
$6.90
$5.19
Analyst Decision
Buy
Strong Buy
Analyst Count
1
9
Target Price
$11.00
$14.43
AVG Volume (30 Days)
941.0K
1.7M
Earning Date
05-08-2026
03-05-2026
Dividend Yield
2.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.82
N/A
Revenue Next Year
$15.80
$677.91
P/E Ratio
$53.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.98
$1.33
52 Week High
$9.32
$6.88

Technical Indicators

Market Signals
Indicator
RPC
CMPX
Relative Strength Index (RSI) 32.99 41.55
Support Level N/A $4.86
Resistance Level $7.88 $5.86
Average True Range (ATR) 0.29 0.29
MACD -0.03 0.01
Stochastic Oscillator 1.50 36.26

Price Performance

Historical Comparison
RPC
CMPX

About RPC Ridgepost Capital Inc. Class A Common Stock

Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: